Top Markets
Coin of the day
TCR2 Therapeutics Inc. TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc.

TCRR
Peringkat dalam Saham #27038
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on... TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Furthermore, TCR2 Therapeutics has concluded preclinical development for TC-510, another TRuC-T cell specifically engineered to target mesothelin on solid tumors. They are also advancing TC-520, a CD70-targeting TRuC-T cell designed with fratricide resistance for treating renal cell carcinoma. Founded in 2015, the company, formerly known as TCR2, Inc. until its name change in November 2016, is headquartered in Cambridge, Massachusetts.
Harga Saham
$1.48
Terakhir disinkronkan: 2023-05-31
Kapitalisasi Pasar
$35.54M
Perubahan (1 hari)
-5.73%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan TCR2 Therapeutics Inc. (TCRR)

Kategori

Riwayat pemecahan saham untuk TCR2 Therapeutics Inc. (TCRR)
Saham TCR2 Therapeutics Inc. (simbol: TCRR) telah mengalami total 0 kali pemecahan saham.
Pemecahan saham terbaru terjadi pada Aug 20, 2026.
Satu lembar saham TCRR yang dibeli sebelum Aug 20, 2026 sekarang setara dengan 0 lembar saham TCRR.
Daftar pemecahan saham
Tahun Pemecahan Kelipatan Kelipatan Kumulatif
Tidak cukup data untuk tanggal yang disediakan.
Pemecahan saham untuk perusahaan sejenis atau pesaing
Perusahaan Jumlah pemecahan saham Kelipatan Kumulatif Negara
1 x2
US
0 -
US
0 -
NL
1 x3
AU
0 -
CH